Early-Stage Biopharma Investors Opt for Safer Bets in 2002
This article was originally published in Start Up
Executive Summary
Discovery risk is for VCs like yesterday's newspaper. With the Big Pharma market for discovery tools abysmally quiet, early-stage funding for such firms saw a steep decline.